• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    LeMaitre Vascular Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/3/25 5:01:33 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care
    Get the next $LMAT alert in real time by email
    lmat20250603_8k.htm
    false 0001158895 0001158895 2025-06-02 2025-06-02

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     

     
    FORM 8-K
    CURRENT REPORT
     
    PURSUANT TO SECTION 13 OR 15(0) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    Date of report (Date of earliest event reported): June 2, 2025
     

     
    LeMaitre Vascular, Inc.
    (Exact Name of Registrant as Specified in Its Charter)
     

     
    Delaware
    (State or Other Jurisdiction of Incorporation)
     
     
    001-33092 04-2825458
    (Commission File Number) (IRS Employer Identification No.)
       
    63 Second Avenue 01803
    Burlington, Massachusetts (Zip Code)
    (Address of Principal Executive Offices)  
     
     
    (781) 221-2266
    (Registrant's Telephone Number, Including Area Code)
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Exchange Act:
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common
    LMAT
    The Nasdaq Global Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. D
     
     

     
     
    Item 5.07. Submission of Matters to a Vote of Security Holders.
     
    (a)      On June 2, 2025, the Company held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 22,594,362 shares of the Company's common stock were entitled to vote as of April 8, 2025, the record date for the Annual Meeting, of which 21,068,573 shares were present in person or represented by proxy at the Annual Meeting.
     
    (b)      Matters voted upon by the stockholders at the Annual Meeting were: (i) the election of three Class I directors nominated by the Board of Directors for three-year terms; (ii) an advisory vote on the compensation of the Company's named executive officers; (iii) an advisory vote on the frequency of future advisory votes on executive compensation; and (iv) the ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for 2025.
     
    Set forth below is information concerning each matter submitted to a vote at the Annual Meeting.
     
    Proposal No.1 – Election of Directors
     
    By a majority of votes cast, the stockholders elected the following three nominees as Class I directors for a term of three years expiring upon the 2028 Annual Meeting of Stockholders or until their successor has been duly elected and qualified. George W. LeMaitre received a vote of 18,389,000.35701 shares for, 1,621,733 shares withheld and 1,057,839 broker non-votes. David B. Roberts received a vote of 18,223,556 shares for, 1,787,178 shares withheld and 1,057,839 broker non-votes. Martha Shadan received a vote of 15,217,924 shares for, 4,792,810 shares withheld and 1,057,839 broker non-votes.
     
    Proposal No. 2 – Advisory Vote on Executive Compensation
     
    By a majority of votes cast, the stockholders approved, on an advisory basis, the Company's executive compensation by a vote of 19,060,967 shares for and 913,117 shares against, 36,649 shares abstaining, and 1,057,839 broker non-votes.
     
    Proposal No.3 – Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation
     
    By a majority of votes cast, the stockholders approved, on an advisory basis, a frequency of “1 Year” for future advisory votes on executive compensation by a vote of:
     
    1 Year:
    16,990,007     
    2 Years:
    18,302     
    3 Years:
    2,972,329     
    Abstain:
    30,096     
     
     
    Proposal No.4 – Ratification of the Selection of Independent Registered Public Accounting Firm
     
    By a majority of votes cast, the stockholders ratified the selection of Grant Thornton LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025, with a vote of 21,006,527 shares for, 43,143 shares against, and 18,903 shares abstaining.
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Dated: June 3, 2025
    LEMAITRE VASCULAR, INC.
    By:
    /s/ Dorian P. LeBlanc
    Name:      Dorian P. LeBlanc
    Title:        Chief Financial Officer
     
     
     
    Get the next $LMAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LMAT

    DatePrice TargetRatingAnalyst
    2/28/2025Outperform → Perform
    Oppenheimer
    2/28/2025Outperform → Mkt Perform
    Barrington Research
    2/13/2025$95.00Equal Weight
    Wells Fargo
    10/15/2024$96.00Neutral
    Cantor Fitzgerald
    8/2/2024$85.00 → $105.00Buy
    Lake Street
    5/31/2024$100.00Buy
    ROTH MKM
    4/26/2024$59.00 → $75.00Hold → Buy
    Stifel
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $LMAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Shadan Martha

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      6/2/25 4:27:51 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Roush John A

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      6/2/25 4:27:06 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Ross Bridget A

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      6/2/25 4:25:24 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Leadership Updates

    Live Leadership Updates

    See more
    • Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

      GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

      3/20/25 9:00:00 AM ET
      $LMAT
      $POCI
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Former Johnson & Johnson Executive Joins Advisory Board at Maitri Health Technologies

      Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and

      3/23/21 8:00:00 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by LeMaitre Vascular Inc.

      SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)

      10/22/24 3:49:21 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

      SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

      2/13/24 5:08:02 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

      SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

      2/12/24 3:02:21 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Financials

    Live finance-specific insights

    See more
    • LeMaitre Q1 2025 Financial Results

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa

      5/1/25 4:05:32 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025

      BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and ser

      4/7/25 3:56:16 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Q4 2024 Financial Results

      BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+25%), and provided guidance. Q4 2024 Financial Results Sales $55.7mm, +14% (+14% organic) vs. Q4 2023Gross margin 69.3%, +121 bpsOp. income $12.9mm, +26%Op. margin 23%Earnings per diluted share $0.49, +30%Cash up $175.8mm sequentially to $299.7mm Grafts (+23%), carotid shunts (+14%) and catheters (+12%) drove Q4 sales growth. APAC sales increased 21%, EMEA 18% and the Americas 12%. XenoSure patches received Chinese cardiac approval in December. The gross margin im

      2/27/25 4:05:29 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    SEC Filings

    See more
    • LeMaitre Vascular Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)

      6/3/25 5:01:33 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by LeMaitre Vascular Inc.

      SD - LEMAITRE VASCULAR INC (0001158895) (Filer)

      5/30/25 7:00:12 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by LeMaitre Vascular Inc.

      10-Q - LEMAITRE VASCULAR INC (0001158895) (Filer)

      5/8/25 4:02:12 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference

      BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare Conference on Tuesday, May 13, 2024, at 5:00 PM PDT at the Encore at the Wynn Hotel in Las Vegas, NV. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre

      5/5/25 4:39:09 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Q1 2025 Financial Results

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa

      5/1/25 4:05:32 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025

      BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and ser

      4/7/25 3:56:16 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lemaitre Vascular downgraded by Oppenheimer

      Oppenheimer downgraded Lemaitre Vascular from Outperform to Perform

      2/28/25 8:28:09 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Lemaitre Vascular downgraded by Barrington Research

      Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform

      2/28/25 7:39:54 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Lemaitre Vascular with a new price target

      Wells Fargo initiated coverage of Lemaitre Vascular with a rating of Equal Weight and set a new price target of $95.00

      2/13/25 7:09:15 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care